K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region

Leukemia Research

Volumn 27, Issue 11, 2003, Pages 1027-1038

  Day, Noel E ^a,b   Ugai, Hideyo ^b   Yokoyama, Kazunari K ^b   Ichiki, Albert T ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b ANB Tsukuba Institute   (Japan)

Author keywords

CIITA; CIITA promoter IV; IFN inducible; K 562; MHC class II

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSACTIVATOR PROTEIN;

ALTERNATIVE RNA SPLICING; ANTIGEN EXPRESSION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN K 562; CONTROLLED STUDY; GENE INSERTION; GENE SEQUENCE; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NULL ALLELE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; UPREGULATION;

EID: 0037972039     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00072-9     Document Type: Article

References (47)

1. Ting J.P., Baldwin A.S. Regulation of MHC gene expression. Curr. Opin. Immunol. 5:1993;8-16.
2. Mach B., Steimle V., Martinez-Soria E., Reith W. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:1996;301-331.
3. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 45:1975;321-334.
4. Lozzio C.B., Lozzio B.B., Yang W.K., Ichiki A.T., Bamberger E.G. Absence of thymus-derived lymphocyte markers in myelogenous leukemia (Ph1+) cell line K-562. Cancer Res. 36:1976;4657-4662.
5. Tetteroo P.A.T., Massaro F., Mulder A., Schreuder-van Gelder R., von dem Borne A.E.G.K. Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells. Leuk. Res. 8:1984;197-206.
6. Sutherland J.A., Turner A.R., Mannoni P., McGann L.E., Turc J.M. Differentiation of K562 leukemia cells along erythroid, macrophage, and megakaryocyte lineages. J. Biol. Response Mod. 5:1986;250-262.
7. Lozzio B.B., Lozzio C.B., Bamberger E.G., Feliu A.S. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 166:1981;546-550.
8. Wakasugi H., Harel A., Dokhelar M.C., Fradelizi D., Tursz T. Leukemia cell lines can replace monocytes for mitogen-induced T-lymphocyte responses: this accessory function is dependent upon their differentiation stage. Proc. Natl. Acad. Sci. U.S.A. 80:1983;6028-6031.
9. Wakasugi H., Harel A., Dokhelar M.C., Fradelizi D., Tursz T. Accessory function and interleukin 1 production by human leukemic cell lines. J. Immunol. 132:1984;2939-2947.
10. Baker E.J., Ichiki A.T., Hodge J.W., Sugantharaj D., Bamberger E.G., Lozzio C.B. PMA-treated K-562 leukemia cells mediate a TH2-specific expansion of CD4+ T cells in vitro. Leuk. Res. 24:2000;1049-1057.
11. Benz E.J. Jr., Murnane M.J., Tonkonow B.L., Berman B.W., Mazur E.M., Cavallesco C.et al. Embryonic-fetal erythroid characteristics of a human leukemic cell line. Proc. Natl. Acad. Sci. U.S.A. 77:1980;3509-3513.
12. Drew S.I., Terasaki P.I., Billing R.J., Bergh O.J., Minowada J., Klein E. Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker. Blood. 49:1977;715-718.
13. Garson D., Dokhelar M.C., Wakasugi H., Mishal Z., Tursz T. HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon. Exp. Hematol. 13:1985;885-890.
14. Klein G., Zeuthen J., Eriksson I., Terasaki P., Bernoco M., Rosen A.et al. Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J. Natl. Cancer Inst. 64:1980;725-735.
15. Lozzio BB, Lozzio CB, Ichiki AT, Kalmaz GD, Bamberger EG. K-562: a pluripotent leukemia stem cell line of human origin. In: Killmann S-A, Cronkite EP, Muller-Berat CN, editors. Proceedings of the Alfred Benzon Symposium on Hematopoietic Stem Cells, vol. 18. Copenhagen: Munksgaard; 1983. p. 323-37.
16. Maziarz R.T., Mentzer S.J., Burakoff S.J., Faller D.V. Distinct effects of interferon-gamma and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killer-mediated lysis. Cell Immunol. 130:1990;329-338.
17. Ichiki A.T., Lozzio C.B., Barnhill M.A., Wust C.J., Bamberger E.G., Trent D.J.et al. Interferon-gamma-induced expression of class I HLA antigens on K-562 cells grown in serum-free medium. J. Interferon Res. 7:1987;87-93.
18. Sutherland J., Mannoni P., Rosa F., Huyat D., Turner A.R., Fellous M. Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate. Hum. Immunol. 12:1985;65-73.
19. Steimle V., Otten L.A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 75:1993;135-146.
20. Itoh-Lindstrom Y., Piskurich J.F., Felix N.J., Wang Y., Brickey W.J., Platt J.L.et al. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. J. Immunol. 163:1999;2425-2431.
21. Louis-Plence P., Moreno C.S., Boss J.M. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J. Immunol. 159:1997;3899-3909.
22. Masternak K., Muhlethaler-Mottet A., Villard J., Zufferey M., Steimle V., Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14:2000;1156-1166.
23. Reith W., Siegrist C.A., Durand B., Barras E., Mach B. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc. Natl. Acad. Sci. U.S.A. 91:1994;554-558.
24. Zhu X.S., Linhoff M.W., Li G., Chin K.C., Maity S.N., Ting J.P. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol. Cell Biol. 20:2000;6051-6061.
25. Durand B., Sperisen P., Emery P., Barras E., Zufferey M., Mach B.et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1997;1045-1055.
26. Masternak K., Barras E., Zufferey M., Conrad B., Corthals G., Aebersold R.et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20:1998;273-277.
27. Steimle V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B.et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1995;1021-1032.
28. Muhlethaler-Mottet A., Otten L.A., Steimle V., Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:1997;2851-2860.
29. Morris A.C., Spangler W.E., Boss J.M. Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J. Immunol. 164:2000;4143-4149.
30. Muhlethaler-Mottet A., Di Berardino W., Otten L.A., Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity. 8:1998;157-166.
31. Xi H., Eason D.D., Ghosh D., Dovhey S., Wright K.L., Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 18:1999;5889-5903.
32. Riley J.L., Westerheide S.D., Price J.A., Brown J.A., Boss J.M. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity. 2:1995;533-543.
33. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 265:1994;106-109.
34. Zhou H., Glimcher L.H. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity. 2:1995;545-553.
35. Hake S.B., Masternak K., Kammerbauer C., Janzen C., Reith W., Steimle V. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Mol. Cell Biol. 20:2000;7716-7725.
36. Linhoff M.W., Harton J.A., Cressman D.E., Martin B.K., Ting J.P. Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains. Mol. Cell Biol. 21:2001;3001-3011.
37. Quan V., Towey M., Sacks S., Kelly A.P. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA. Immunogenetics. 49:1999;957-963.
38. Harton P.A., Cressman D.E., Chin K.C., Der C.J., Ting J.P. GTP binding by class II transactivator: role in nuclear import. Science. 285:1999;1402-1405.
39. Sambrook J, Fritsch EF, Maniatis TA. Molecular cloning: a laboratory manual, vols. 1-3, 2nd ed. New York: Cold Springs Harbor; 1989.
40. Orlando V., Strutt H., Paro R. Analysis of chromatin structure by in vivo formaldehyde crosslinking. Methods. 11:1997;205-214.
41. O'Keefe G.M., Nguyen V.T., Ping Tang L.L., Benveniste E.N. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. J. Immunol. 166:2001;2260-2269.
42. Suter T., Malipiero U., Otten L., Ludewig B., Muelethaler-Mottet A., Mach B.et al. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 30:2000;794-802.
43. Dong Y., Rohn W.M., Benveniste E.N. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes. J. Immunol. 162:1999;4731-4739.
44. Liu A., Takahashi M., Toba K., Zheng Z., Hashimoto S., Nikkuni K.et al. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells. Hematol. Oncol. 17:1999;149-160.
45. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 215:1990;403-410.
46. Piskurich J.F., Lin K.I., Lin Y., Wang Y., Ting J.P., Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol. 1:2000;526-532.
47. Goodwin B.L., Xi H., Tejiram R., Eason D.D., Ghosh N., Wright K.L.et al. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 12:2001;327-335.